NCT02307695View on ClinicalTrials.gov

The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes

PHASE4UnknownINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Type 1 Diabetes
Interventions
DRUG

Saxagliptin

saxagliptin 5 mg p.o. qd, 24 week

DRUG

Insulin

Patients will be treated according to routine clinical practice at the discretion of the treating physician.

Trial Locations (1)

210029

RECRUITING

First Affiliated Hospital, Nanjing Medical University, Nanjing

Sponsors
All Listed Sponsors
lead

Nanjing Medical University

OTHER